State Street Corporation filed a Schedule 13G with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing its beneficial ownership position in Cisco Systems Inc as of September 30, 2026.
State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing a beneficial ownership position in Collegium Pharmaceutical Inc as of September 30, 2026.
State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing a beneficial ownership position in the common stock of Commerce Bancshares Inc/MO as of September 30, 2026.
WhiteFiber, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, covering the company's financial condition and operations as a data center and cloud services provider.
Cellectar Biosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, reporting condensed consolidated financial statements and related disclosures.
State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 2,930,133 shares of Cullen/Frost Bankers Inc common stock as of September 30, 2026.
State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 1,717,200 shares of common stock in Contango Silver & Gold Inc., representing 5.1% of the class, as of the triggering event date of September 30, 2026.
State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 7,737,938 shares of Compass Therapeutics Inc common stock as of September 30, 2026.
State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 3,331,535 shares of Corvus Pharmaceuticals Inc. common stock as of September 30, 2026.
State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 4,994,047 shares of CRISPR Therapeutics AG common stock as of September 30, 2026.